Sharon Brown
Adult Health · Vineland, NJNPI 1437487907
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,774 of the $11,393 with a category attached, or 77.0%. 34 manufacturers reported payments, led by Medtronic at 40.8% of the total. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 525 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- AbbVie$2K
- AstraZeneca$966
- GSK$569
- Pfizer$516
- Novo Nordisk$387
- plus $3K from 28 others
What the payments were for
- Travel & lodging$2,61923%
- Food & beverage$8,77477%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 60 | $4,646 |
| AbbVie | 120 | $1,518 |
| AstraZeneca | 36 | $966 |
| GSK | 44 | $569 |
| Pfizer | 47 | $516 |
| Novo Nordisk | 39 | $387 |
| Biohaven Pharmaceutical Holding Company Ltd. | 21 | $348 |
| Lilly USA, LLC | 24 | $319 |
| Bayer | 14 | $284 |
| Amgen | 15 | $227 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $193 |
| Biohaven Pharmaceuticals, Inc. | 6 | $184 |
| Boehringer Ingelheim | 9 | $123 |
| Shield Therapeutics Inc | 2 | $110 |
| Kowa Pharmaceuticals America, Inc. | 7 | $104 |
| Daiichi Sankyo Inc. | 7 | $93 |
| Astellas Pharma US Inc | 6 | $92 |
| Merck | 6 | $89 |
| Lundbeck LLC | 5 | $80 |
| Nestle Healthcare Nutrition Inc. | 5 | $67 |
| Philips North America LLC | 4 | $65 |
| Idorsia Pharmaceuticals US Inc | 4 | $64 |
| Evoke Pharma, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Exact Sciences | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 3 | $30 |
| Eisai Inc. | 2 | $28 |
| Dexcom, Inc. | 2 | $25 |
| Seqirus USA Inc | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$2,844
- FARXIGA$433
- BREZTRI$433
- NURTEC ODT$241
- VRAYLAR$237
- FASENRA$136
- AIRSUPRA$127
- ENDURANT IIS$109
How this compares
$11,393 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 54 | $57,263 |
| JardianceEmpagliflozin | 60 | $52,996 |
| EliquisApixaban | 59 | $37,263 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $26,921 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $24,026 |
| EntrestoSacubitril/Valsartan | 31 | $23,971 |
| FarxigaDapagliflozin Propanediol | 20 | $23,601 |
| OzempicSemaglutide | 12 | $20,987 |
| TradjentaLinagliptin | 22 | $17,037 |
| LinzessLinaclotide | 23 | $15,354 |
| Bydureon BciseExenatide Microspheres | 18 | $14,291 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $5,480 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $5,245 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 214 | $5,229 |
| Atorvastatin Calcium | 432 | $4,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $123 | $70,03382 claims |
| MerckJanuvia | $89 | $57,26354 claims |
| PfizerEliquis | $516 | $37,26359 claims |
| GSKTrelegy Ellipta | $569 | $26,92138 claims |
| AstraZenecaFarxiga | $966 | $23,60120 claims |
| Novo NordiskOzempic | $387 | $20,98712 claims |
| AbbVieLinzess | $1,518 | $15,35423 claims |
| Lilly USA, LLCHumalog | $319 | $2,01616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Vineland
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.